EyeGate Pharma raises $22.6 million series D for dry eye product
This article was originally published in Scrip
Executive Summary
EyeGate Pharma, a privately held US company developing ocular therapeutics, has secured $22.6 million in a series D financing. The funding will be used to continue development of EGP-437 for the treatment of dry eye syndrome (DES) using the company's EyeGate II Delivery System.